The depressed brain encourages rigid thought patterns that impact well-being. This can be viewed as a “landscape” with deep wells that make it difficult for patients to “move between” different thoughts and perspectives.
Image by Richard Daws, Kings College London
Psilocybin therapy “flattens” the brain’s landscape and “opens up” the rigidity of the depressed to allow new thoughts, insight, and perspectives to emerge.
Image by Richard Daws, Kings College London
Post-treatment, a flatter landscape makes it easier for patients to experience healthier flexibility and diversity in their thought patterns.
Image by Richard Daws, Kings College London
Study Suggests New Mechanism for How Psychedelics Affect the Brain
Psilocybin fosters greater connections between different regions of the brain in depressed people, freeing them up from long-held patterns of rumination and excessive self-focus, according to a new study by scientists at UC San Francisco and Imperial College London.
The discovery points toward a general mechanism through which psychedelics may be acting therapeutically on the brain to alleviate depression and possibly other psychiatric conditions that are marked by fixed patterns of thinking.
Scientists analyzed fMRI brain scans from nearly 60 people who had participated in two psilocybin trials. In the first one, all the participants had treatment-resistant depression and knew they were being given psilocybin. In the second one, the participants were depressed but not as severely, and they were not told whether they had been given psilocybin or a placebo that turned out to be escitalopram, an SSRI antidepressant. In addition to the drugs, all the participants received the same type of psychotherapy.
The scans, which were done before and after treatment, showed the psilocybin treatment reduced connections within brain areas that are tightly connected in depression, including the default mode, salience, and executive networks, and increased connections to other regions of the brain that had not been well integrated.
Participants were also less emotionally avoidant and their cognitive functioning got better. The improvement in their depressive symptoms correlated with changes to their brains, and these changes lasted until the study ended three weeks after the second psilocybin dose. No such changes were seen in the brains of those who received escitalopram, suggesting that psilocybin acts differently on the brain than SSRIs.
Psilocybin and other serotonergic psychedelics like ayahuasca affect 5-HT2A receptors, which are plentiful in brain networks that become overactive in depression. One hypothesis is that the drugs briefly disrupt these connections, giving them a chance to reform in new ways in the ensuing days and weeks.
“In previous studies we had seen a similar effect in the brain when people were scanned whilst on a psychedelic, but here we’re seeing it weeks after treatment for depression, which suggests a carry-over of the acute drug action,” said Robin Carhart-Harris, PhD, who directs the Neuroscape Psychedelics Division at UCSF and is the senior author of the study, which appears April 11, 2022, in Nature Medicine.
“We don’t yet know how long the changes in brain activity seen with psilocybin therapy last, and we need to do more research to understand this,” said Carhart-Harris, who is the Ralph Metzner Distinguished Professor of Neurology, Psychiatry, and Behavioral Sciences and a member of the UCSF Weill Institute for Neurosciences. “We do know that some people relapse, and it may be that after a while their brains revert to the rigid patterns of activity we see in depression.”
The authors caution that while these findings are encouraging, patients with depression should not attempt to self-medicate with psilocybin. The trials took place under controlled, clinical conditions, using a regulated dose formulated in a laboratory, and involved extensive psychological support before, during, and after dosing.
But the study points to a mechanism that, if it holds up, may explain both how psilocybin helps to alleviate depression and potentially other debilitating psychiatric conditions.
“For the first time we find that psilocybin works differently from conventional antidepressants – making the brain more flexible and fluid, and less entrenched in the negative thinking patterns associated with depression,” said David Nutt, DM, head of the Imperial Centre for Psychedelic Research. “This supports our initial predictions and confirms psilocybin could be a real alternative approach to depression treatments.”
Original Article: Psilocybin Rewires the Brain for People with Depression
More from: University of California San Francisco | Imperial College London
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Psilocybin
- U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening
Blunt to speak on the importance of understanding psilocybin’s potential role in mental health, reducing barriers to continued research in psychedelic ...
- Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study
As part of this study, the researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson’s.
- Albert Labs secures psilocybin licence from Health Canada
"This is an important milestone for Albert Labs; it firms up our supply chain and provides us with more market opportunities," said ...
- Numinus Wellness granted Health Canada approval for psychedelic-assisted therapy using psilocybin for patient with treatment-resistant depression
The psychedelic-assisted therapy treatment, which the company said has shown a great deal of promise in treating depression in ...
- First patient in Quebec gets approval from Health Canada to treat mental health condition with psilocybin
In Montreal, a pioneering clinic in the emerging field of psychedelic-assisted psychotherapy is about to become the first health-care facility in Quebec to legally treat depression with psilocybin ...
Go deeper with Google Headlines on:
Psilocybin
Go deeper with Bing News on:
Psychedelics
- Psychedelics: How they act on the brain to relieve depression
Up to 30% of people with depression don't respond to treatment with antidepressants. This may be down to differences in biology between patients and the fact that it often takes a long time to respond ...
- This Stanford lecturer discusses time travel, psychedelics and debut novel ‘The Red Arrow’
I want to say, first of all, that I am happy,” is the first thing the narrator of William Brewer’s debut novel, “The Red Arrow,” tells us. Then he settles into a train and begins traveling both ...
- Psychedelics As Treatment Options For Mental Health
"More and more studies reveal that regulated doses of psychedelics like LSD, psilocybin (magic mushrooms), MDMA, or ketamine in controlled settings could be viable treatments for a laundry list of ...
- THE FIRST-EVER MEDICAL PSYCHEDELICS SERIES AT DAVOS 2022 hosted by Energia Holdings Incorporated
As the COVID-19 pandemic laid bare, mental health is one of the largest underserved areas in the medical community. With few solutions in sight, there is a growing body of ...
- The Psychedelics Megatrend Is an Inevitable Boom
In creating a superior treatment for mental health disorders, psychedelics will give birth to a multi-hundred-billion-dollar industry.